



MAYNE PHARMA APPOINTS NEW GROUP CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

9 March 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) has appointed Mr Nick Freeman as Group Chief Financial Officer and Company Secretary, effective 22 May 2017.

Nick is a Chartered Accountant and brings more than 25 years of experience to the role. He has extensive international financial experience across a range of industries including retail, consumer goods, financial services, transport and oil and gas. For the last 10 years, Nick has held a variety of Chief Financial Officer (CFO) roles at ANZ Bank including most recently as CFO Australia, with responsibility for all aspects of financial management across ANZ's largest division. Prior to his current role, Nick was CFO New Zealand at ANZ Bank. He also held the position of Group Treasurer at Qantas Airways and was CFO at General Mills and Millers Retail.

Mayne Pharma's CEO, Mr Scott Richards, said, "I am delighted to appoint Nick to the Group CFO role. Nick brings a broad range of financial and corporate expertise to the role which will be invaluable as we continue our strategy to strengthen and grow our businesses through operational efficiencies, further business and corporate development, and the extraction of revenue and cost synergies from recent acquisitions. Nick has significant experience in the areas of mergers and acquisitions, integration management, tax, financial planning and reporting, risk management, treasury and investor relations. I am confident he will be a strong addition to the Mayne Pharma leadership team and I look forward to growing the business further with Nick's support."

"The Board and I would like to thank Mark Cansdale for his outstanding contribution to the Company over the past six years and wish him every success for the future. Mark will work closely with Nick to ensure a smooth transition following his commencement in May."

Nick holds a Bachelor of Commerce from the University of Melbourne, a Graduate Diploma in Management from Monash University and is a Chartered Accountant.

For further information contact:

Scott Richards +61 8 8209 2410

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.